BioLargo Q3 Loss Narrows to $3.8M, But Going Concern Reaffirmed as Cash Falls to $1.5M
BLGO is trading near its 52-week low of $0.062 (9.7% above the low).
Summary
BioLargo posted a $3.8M Q3 loss and $3.5M of nine-month revenue, with cash down to $1.5M and a reaffirmed going-concern warning. Post-quarter it raised more money through Clearthink share sales and Clyra debt.
Key Events · Earnings and Guidance · BLGO
-
Q3 Loss Narrows on Prior-Year Charge
Net loss was $3,824,000 versus $7,244,000 a year earlier, but the 2025 quarter included a $3,849,000 credit loss expense; excluding it, the loss widened by $429,000.
-
Revenue Falls 52% Year to Date
Nine-month revenue was $3,452,000 versus $7,148,000, driven by lower private-label pet odor product sales, partly offset by higher engineering service revenue.
-
Cash Drops to $1.5M, Going Concern Reaffirmed
Cash fell to $1,533,000 from $3,883,000 at December 31, 2025, with a $2,391,000 working capital deficit and substantial doubt about the ability to continue as a going concern.
-
Clyra Debt Drives Liabilities Higher
Total liabilities rose to $11,965,000 from $6,785,000, including $4,876,000 of long-term Clyra Medical debt obligations; nine-month interest expense was $790,000 versus $352,000.
Analysis · BLGO · Industrial Applications And Services
The headline improvement is optical: BioLargo's third-quarter loss of $3.8M compares with last year's $7.2M only because the prior-year quarter carried a $3.8M credit loss charge. Strip that out and the loss actually widened by $429,000, as Clyra Medical's spending, R&D and interest costs climbed. The balance sheet tells the real story. Cash dropped from $3.9M at year-end to $1.5M, working capital is negative $2.4M, and total liabilities nearly doubled to $12.0M as Clyra's debt load grew. Management again states substantial doubt about continuing as a going concern, and the company is funding itself through equity lines and subsidiary debt rather than operations. Since quarter-end it has kept selling stock to Clearthink ($254,000 for 3.6M shares) and raised another $768,000 of Clyra notes plus $200,000 of SAFEs, so dilution and leverage keep building.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLGO was trading at $0.07 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $23M. The 52-week trading range was $0.06 to $0.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.